{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105012","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.248169+00:00","generated_at":"2026-05-17T17:30:49.382651+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sight Sciences Q2 2025 revenue $19.6M (-8% YoY), raises FY25 revenue guidance to $72-76M","bullets":["Net loss $11.9M ($0.23 loss per share) vs $12.3M loss in prior year.","Surgical Glaucoma revenue $19.2M (-5% YoY); ordering accounts hit record 1,174, up 4%.","Dry Eye revenue fell to $0.3M from $1.1M as company focuses on reimbursed TearCare access.","Adjusted operating expenses $24.4M, down 8% YoY; reaffirmed FY25 guidance of $101-105M.","Tariff exposure on China products reduced from prior estimate of $3.5-4.5M to $1.0-1.5M for FY25."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105012","json":"https://secwatch.observer/filing/0000950170-25-105012.json","markdown":"https://secwatch.observer/filing/0000950170-25-105012.md","text":"https://secwatch.observer/filing/0000950170-25-105012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000095017025105012/0000950170-25-105012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000095017025105012/sght-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:30:49.382651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}